Nichtalkoholische Fettleber – Volkskrankheit mit hohem kardiometabolischen Risiko

Zusammenfassung

Die Genese der nichtalkoholischen Fettleber­erkrankung (NAFLD) ist ein multifaktorielles Geschehen, an dem neben einem dysfunk­tionalen Fettgewebe die De-novo-Lipogenese aus Kohlenhydraten einen entschei­den­den Anteil hat. Die NAFLD ist ein Risikofaktor für Typ-2-Diabetes, kardiovaskuläre Erkankungen und chronische Nieren­erkrankungen.

Schlüsselwörter

Nichtalkoholische Fettleber - Typ-2-Diabetes - Lipolyse - Kohlenhydrate - De-novo-Lipogenese

• Literatur

• 1 Levene AP, Goldin RD. The epidemiology, pathogenesis and histopathology of fatty liver disease. Histopathology 2012; 61(2): 141-152
• 2 Stefan N, Häring HU. The metabolically benign and malignant fatty liver. Diabetes 2011; 60(8): 2011-2017
• 3 Ströhle A, Stein J. Nichtalkoholische Fettlebererkrankung. Pathophysiologisch orientierte Diagnostik und Therapie. Med Monatsschr Pharm 2015; 38(5): 166-178
• 4 Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol 2015; 62(1 Suppl): 47-64
• 5 Taylor R. Type 2 Diabetes: Etiology and reversibility. Diabetes Care 2013; 36(4): 1047-1055
• 6 Taylor R. Banting Memorial lecture 2012: reversing the twin cycles of type 2 diabetes. Diabet Med 2013; 30(3): 267-275
• 7 Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013; 10(6): 330-344
• 8 Jäger S, Jacobs S, Kroger J et al. Association between the Fatty Liver Index and Risk of Type 2 Diabetes in the EPIC-Potsdam Study. PLoS One 2015; 10(4): e0124749
• 9 Byrne CD, Targher G. Ectopic fat, insulin resistance, and nonalcoholic fatty liver disease: implications for cardiovascular disease. Arterioscler Thromb Vasc Biol 2014; 34(6): 1155-1161
• 10 Than NN, Newsome PN. A concise review of non-alcoholic fatty liver disease. Athero­sclerosis 2015; 239(1): 192-202
• 11 Targher G, Chonchol MB, Byrne CD. CKD and nonalcoholic fatty liver disease. Am J Kidney Dis 2014; 64(4): 638-652
• 12 Musso G, Gambino R, Tabibian JH et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med 2014; 11(7): e1001680
• 13 Yki-Jarvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol 2014; 2(11): 901-910
• 14 Chalasani N, Younossi Z, Lavine JE et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012; 142(7): 1592-1609
• 15 Vos B, Moreno C, Nagy N et al. Lean non-alcoholic fatty liver disease (Lean-NAFLD): a major cause of cryptogenic liver disease. Acta Gastroenterol Belg 2011; 74(3): 389-394
• 16 Younossi ZM, Stepanova M, Negro F et al. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine (Baltimore) 2012; 91(6): 319-327
• 17 Fukuda T, Hamaguchi M, Kojima T et al. The impact of non-alcoholic fatty liver disease on incident type 2 diabetes mellitus in non-overweight individuals. Liver Int 2015; [Epub ahead of print]
• 18 Donnelly KL, Smith CI, Schwarzenberg SJ et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005; 115(5): 1343-1351
• 19 Cao Y. Angiogenesis as a therapeutic target for obesity and metabolic diseases. Chem Immunol Allergy 2014; 99: 170-179
• 20 Goossens GH, Blaak EE. Adipose tissue dysfunction and impaired metabolic health in human obesity: a matter of oxygen?. Front Endocrinol (Lausanne) 2015; 6: 55
• 21 Moreno-Indias I, Tinahones FJ. Impaired adipose tissue expandability and lipogenic capacities as one of the main causes of metabolic disorders. J Diabetes Res 2015; 2015: 970375
• 22 Grant RW, Stephens JM. Fat in flames: influence of cytokines and pattern recognition receptors on adipocyte lipolysis. Am J Physiol Endocrinol Metab 2015; 309(3): 205-213
• 23 Perry RJ, Samuel VT, Petersen KF, Shulman GI. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature 2014; 510(7503): 84-91
• 24 Shulman GI. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N Engl J Med 2014; 371(12): 1131-1141
• 25 Eissing L, Scherer T, Todter K et al. De novo lipogenesis in human fat and liver is linked to ChREBP-beta and metabolic health. Nat Commun 2013; 4: 1528
• 26 Zong G, Zhu J, Sun L et al. Associations of erythrocyte fatty acids in the de novo lipogenesis pathway with risk of metabolic syndrome in a cohort study of middle-aged and older Chinese. Am J Clin Nutr 2013; 98(2): 319-326
• 27 Jacobs S, Jager S, Jansen E et al. Associations of Erythrocyte Fatty Acids in the De Novo Lipogenesis Pathway with Proxies of Liver Fat Accumulation in the EPIC-Potsdam Study. PLoS One 2015; 10(5): e0127368
• 28 Lambert JE, Ramos-Roman MA, Browning JD, Parks EJ. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology 2014; 146(3): 726-735
• 29 Schwarz JM, Linfoot P, Dare D, Aghajanian K. Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets. Am J Clin Nutr 2003; 77(1): 43-50
• 30 Martens EA, Gatta-Cherifi B, Gonnissen HK, Westerterp-Plantenga MS. The potential of a high protein-low carbohydrate diet to pre­serve intrahepatic triglyceride content in ­healthy humans. PLoS One 2014; 9(10): e109617
• 31 Chiu S, Sievenpiper JL, de Souza RJ et al. ­Effect of fructose on markers of non-­alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of controlled feeding trials. Eur J Clin Nutr 2014; 68(4): 416-423
• 32 Chung M, Ma J, Patel K, Berger S et al. Fructose, high-fructose corn syrup, sucrose, and nonalcoholic fatty liver disease or indexes of liver health: a systematic review and meta-analysis. Am J Clin Nutr 2014; 100(3): 833-849
• 33 Cao Y. Angiogenesis and vascular functions in modulation of obesity, adipose metabolism, and insulin sensitivity. Cell Metab 2013; 18(4): 478-489
• 34 Petersen KF, Dufour S, Savage DB et al. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc Natl Acad Sci USA 2007; 104(31): 12587-12594
• 35 Samuel VT, Shulman GI. Mechanisms for insulin resistance: common threads and missing links. Cell 2012; 148(5): 852-871
• 36 Green CJ, Hodson L. The influence of dietary fat on liver fat accumulation. Nutrients 2014; 6(11): 5018-5033
• 37 Monteiro J, Leslie M, Moghadasian MH et al. The role of n-6 and n-3 polyunsaturated fatty acids in the manifestation of the metabolic syndrome in cardiovascular disease and non-alcoholic fatty liver disease. Food Funct 2014; 5(3): 426-435
• 38 Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology 2014; 146(6): 1513-1524
• 39 Roeb E, Steffen HM, Bantel H, Baumann U. S2k Leitlinie: Nicht-alkoholische Fett­lebererkrankungen. AWMF Leitlinie Register Nr 021-025 2015
• 40 Ferramosca A, Zara V. Modulation of hepatic steatosis by dietary fatty acids. World J Gastroenterol 2014; 1746-1755